Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
128.12
+0.08 (0.06%)
At close: Apr 28, 2026, 4:00 PM EDT
128.00
-0.12 (-0.09%)
After-hours: Apr 28, 2026, 5:21 PM EDT
Neurocrine Biosciences Stock Forecast
Stock Price Forecast
The 22 analysts with 12-month price forecasts for Neurocrine Biosciences stock have an average target of 180.91, with a low estimate of 140 and a high estimate of 242. The average target predicts an increase of 41.20% from the current stock price of 128.12.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Neurocrine Biosciences stock from 22 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 12 | 12 | 11 | 11 | 10 |
| Buy | 8 | 8 | 6 | 8 | 8 | 9 |
| Hold | 1 | 2 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 22 | 21 | 22 | 22 | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Maintains $160 → $170 | Buy | Maintains | $160 → $170 | +32.69% | Apr 22, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $173 → $185 | Hold | Maintains | $173 → $185 | +44.40% | Apr 10, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $204 → $242 | Strong Buy | Maintains | $204 → $242 | +88.89% | Apr 7, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $164 → $200 | Strong Buy | Maintains | $164 → $200 | +56.10% | Apr 7, 2026 |
| Wedbush | Wedbush | Buy Maintains $151 → $166 | Buy | Maintains | $151 → $166 | +29.57% | Apr 7, 2026 |
Financial Forecast
Revenue This Year
3.57B
from 2.86B
Increased by 24.73%
Revenue Next Year
4.04B
from 3.57B
Increased by 13.14%
EPS This Year
6.19
from 4.67
Increased by 32.58%
EPS Next Year
8.35
from 6.19
Increased by 34.81%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 4.0B | 5.1B | ||||||
| Avg | 3.6B | 4.0B | ||||||
| Low | 3.2B | 3.4B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 40.2% | 43.8% | ||||||
| Avg | 24.7% | 13.1% | ||||||
| Low | 13.5% | -4.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 7.57 | 14.81 | ||||||
| Avg | 6.19 | 8.35 | ||||||
| Low | 4.26 | 4.58 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 62.1% | 139.1% | ||||||
| Avg | 32.6% | 34.8% | ||||||
| Low | -8.7% | -26.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.